Cox regression analysis of the association between DNA methylation PMRa values (grouped by quartiles) and overall survival or disease-free survival
Significant associations are indicated in bold.
| TAM | Not TAM | Interaction | |||
|---|---|---|---|---|---|
| Hazard ratiob | 95% CI | Hazard ratiob | 95% CI | P | |
| Survival | |||||
| ESR1 | 0.7 | 0.5–1.0 | 1.5 | 1.0–2.4 | 0.0073 |
| ARHI | 1.2 | 0.9–1.7 | 0.6 | 0.3–0.9 | 0.0103 |
| CYP1B1 | 0.7 | 0.5–1.0 | 1.5 | 1.1–2.2 | 0.0046 |
| Disease-free survival | |||||
| ESR1 | 0.7 | 0.5–1.0 | 1.5 | 0.9–2.3 | 0.0134 |
| ARHI | 1.2 | 0.9–1.6 | 0.5 | 0.3–0.8 | 0.0015 |
| CYP1B1 | 0.8 | 0.6–1.1 | 1.5 | 1.1–2.1 | 0.0081 |
a PMR, percentage of fully methylated reference; TAM, tamoxifen; Not TAM, not treated with tamoxifen; CI, confidence interval.
b Covariates include age, stage (I, II, and III/IV), nodes (0, 1–3, and >3), hormone receptor status among TAM-treated patients (1, hormone receptor positive and treated with TAM, 0, otherwise), and hormone receptor status among those not treated with TAM (1, hormone receptor positive and not treated with TAM; 0, otherwise). Age and stage are coded as continuous variables.